Navigation Links
Nektar Therapeutics Reports First Quarter 2009 Financial Results
Date:5/6/2009

usiness, results of operations and financial condition could suffer; and (vi) certain other important risks and uncertainties set forth in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 6, 2009 and the company's most recent Quarterly Report on Form 10-Q to be filed on or about May 8, 2009. Actual results could differ materially from the forward-looking statements contained in this press release. The company undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

    Jennifer Ruddock, 650-631-4954
    Nektar Therapeutics

    Susan Noonan, (212) 966-3650
    SAN Group

                        NEKTAR THERAPEUTICS
          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
           (In thousands, except per share information)
                            (unaudited)

                                                  Three-Months
                                                 Ended March 31,
                                                -----------------
                                                  2009      2008
                                                  ----      ----
    Revenue:
       Product sales and royalties               $6,470   $10,371
       Collaboration and other                    3,241     9,621
                                                  -----     -----
    Total revenue                                 9,711    19,992

    Operating costs and expenses:
       Cost of goods sold                         5,099     7,227
       Other cost of revenue                          -     5,334
       Research and development                  23,890    37,373
       General and administrative                11,020    11,947
                                                 ------    ------
    Total operating cos
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Shimadzu Scientific ... UV-1280 multipurpose UV-visible spectrophotometer. Offering wavelength scanning from ... is ideal for applications in a variety of ... , The user-friendly UV-1280 enables intuitive operation, while ...
(Date:1/22/2015)... 2015 The laboratory information management systems ... a number of technological advancements due to factors such ... need to integrate healthcare systems, and increasing government support ... system integration. Key players in the market focus on ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Dr. Greg Leyer ... 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics in ... is an annual continuing education conference for health care professionals. ... included the topic of probiotics in health. Dr. Leyer spoke ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Introduces RESPeRATE Hypertension ... Device Into Country,s Retail Market, NEW YORK ... today announced that its RESPeRATE(R) hypertension treatment device,clinically-proven ... will launch into retail distribution in the United ...
... Lower Strength of Approved Constipation Drug Offers Potential Treatment ... Option to Americans Suffering from IBS-C, ... SCMP ) today announced that the supplemental,New Drug Application (sNDA) ... treatment of irritable bowel syndrome with,constipation (IBS-C) has been accepted ...
... , WHAT: DENTAL IMPLANT MARKET INSIGHTS ... presentation), WHEN: ... from Millennium Research Group, TO ENROLL: Please use the link below ... 416-364-7776 ext. 123 Millennium Research Group ...
Cached Biology Technology:InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 2InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 3InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 2FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 3FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 4FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 5Dental Implant Market Insights Webinar 2
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security market ... 2014 to 2019. Although the U.S. market holds a larger ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... RIVERSIDE, Calif. University of California, Riverside scientists released ... (ACP) yesterday on campus to help control the spread of ... $1.1 billion citrus industry and citrus trees in home landscapes. ... been released in California. UC Riverside Executive Vice Chancellor ...
... knows about the hazard of decompression sickness (DCS) or "the bends." ... were absorbed by the body during the dive, come out of ... to form in the body. DCS causes many symptoms, and its ... death. , But how do marine mammals, whose very survival depends ...
... goalie, and two opposing players are breaking in alone on ... the linesman skating in on your left, but pay him ... two approaching players. As the action unfolds, how is your ... your focus of attention into multiple "spotlights?" Are you using ...
Cached Biology News:UC Riverside scientists release natural enemy of Asian citrus psyllid 2UC Riverside scientists release natural enemy of Asian citrus psyllid 3UC Riverside scientists release natural enemy of Asian citrus psyllid 4Study examines how diving marine mammals manage decompression 2How do we split our attention? 2
... High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for freezing ... record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
sodium channel, nonvoltage-gated 1 alpha,...
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
Biology Products: